Black Diamond Skiing Explained: Skills, Gear and Best Runs
Despite skiing's complicated phrases, slang, and descriptors when it comes to snow and gear, the sport uses a rather simple ...
Fierce Biotech9d
Servier pays $70M to polish Black Diamond's deprioritized solid tumor prospect
Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...
Asianet Newsable on MSN8d
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High
Shares of Black Diamond Therapeutics, Inc. (BDTX) jumped around 21% as of Wednesday noon after the company announced it had ...
4BDTX : Black Diamond Therapeutics Inks Licensing Pact With French Pharma...
Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...
Black Diamond Therapeutics (NASDAQ:BDTX) Receives Outperform Rating from Wedbush
Wedbush reissued their outperform rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) in a research ...
Black Diamond Therapeutics Shares Surge on Servier Licensing Deal
Black Diamond said Servier will develop and commercialize BDTX-4933, a small molecule designed by the Cambridge, Mass., company to address unmet medical needs in RAF/RAS-mutant solid tumors.
Business Insider9d
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. ...
Yahoo Finance9d
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage ...